Search Results

Cancer Genetics (NASDAQCM: CGIX) - RedChip Global Online CEO Conference Presentation and Investor Q A with Panna Sharma, CEO of Caner Genetics (NASDAQCM: CGIX), an emerging leader in DNA-based cancer diagnostics. By: RedChip Money Report Gentry

Cancer Genetics, Inc.

RUTHERFORD, N.J., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the diagnosis and prediction of treatment outcomes for difficult to diagnose cancers, today announced executives from the company will participate at the following investor conferences in September: The company's investor presentation will be made available in the Investor Relations section of the CGI website

RUTHERFORD, N.J., Oct.

RUTHERFORD, N.J., Aug.

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, will present at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 2:30 p.m

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Mayo Clinic ("Mayo") and Cancer Genetics Inc. (CGIX) today launched OncoSpire Genomics ("OncoSpire"), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing. Individualized medicine and genomic testing give us a fundamental understanding of the inner workings of wellness and disease.

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc.s (CGIX) (CGI or the Company) wholly-owned subsidiary, Cancer Genetics Italia, S.r.l. (CGI Italia), has entered into an agreement with Nikon Instruments S.p.A. (Nikon) for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (FISH) in the Italian market

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (CGIX) (CGI) will present at the UBS Global Healthcare Conference on May 22, 2013 at 12:30 p.m

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (CGIX) (CGI), a leader in oncology-focused personalized medicine, has launched a proprietary urogenital cancer array, UroGenRA, intended for kidney cancer diagnosis and subtyping in its own laboratory

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc., a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share.

Cancer Genetics is pursuing a strategy that differs from Facebook's IPO plan, expert says. A Rutherford, N.J.-based start-up developing tools to diagnose cancer is planning to launch an initial public offering this week under the long shadow of Facebook's long-awaited blockbuster IPO. Cancer Genetics Inc